Evidence map›Paper›PMID 42616099›Full record

ArticleCancer immunology, immunotherapy : CII2026

Correction: Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2.

Guopeng Zhang, Wei Zhang, Xiaohuan Wei, Zhenyu Wang, Feitong Wang, Shishuo Sun, Haiheng Xu, Xiangye Liu, Qing Zhang, Xiaoge Gao

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Guopeng ZhangCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Wei ZhangCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Xiaohuan WeiCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Zhenyu WangCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Feitong WangDepartment of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Jiangsu Province, Xuzhou, 221002, People's Republic of China.
Shishuo SunCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Haiheng XuCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
Xiangye LiuJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. liuxy83@xzhmu.edu.cn.
Qing ZhangCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. qingzhang@xzhmu.edu.cn.
Xiaoge GaoCancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. gaoxiaoge@xzhmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42616099
PMCPMC13490326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.